At the time of sacrifice, organ analysis showed that mice treated with LILRB1 CAR-T cells had significantly lower tumor burden in the spleens compared to the groups after MOCK and CD19 CAR-T cells, and significantly lower tumor burden in the bone marrow compared to the group treated with MOCK T cells (Fig. 7E, Supplementary Fig. 7). Here, LILRB1 is linked to neoplasm.